Role of STAT3 (signal transducer and activator of transcription 3) activation and its regulation by PTPRT (protein receptor tyrosine phosphatase type T) and response to paclitaxel and cetuximab in patients (P) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

被引：0
|
作者：
Cirauqui Cirauqui, B. [1 ]
Bernat Peguera, A. [2 ]
Quer Pi-Sunyer, A. [3 ]
Ramirez Serrano, J. L. [4 ]
Domenech Vinolas, M. [5 ]
Teruel Garcia, I. [5 ]
Quiroga Garcia, V. [5 ]
Margeli Vila, M. [5 ]
Chaib, I. [6 ]
Capdevila Riera, L. [7 ]
Ferrando Diez, A. [5 ]
Plaja Salarich, A. [5 ]
Angelats Company, L. [5 ]
Espana Fernandez, S. [5 ]
Berenguer Peinado, G. [5 ]
Lezcano Rubio, C. [8 ]
Pollan Guisasola, C. [9 ]
Martinez Cardus, A. [5 ]
Rosell Costa, R. [10 ]
Mesia Nin, R. [5 ]
机构：
[1] Germans & Trias Pujol Hlth Sci Res Inst IGTP, Badalona Appl Res Grp Oncol BARGO, Catalan Inst Oncol ICO Badalona, Med Oncol, Badalona, Spain
[2] Germans & Trias Pujol Hlth Sci Res Inst IGTP, Badalona Appl Res Grp Oncol B ARGO, Med Oncol, Badalona, Spain
[3] Germans Trias & Pujol Hosp, Pathol, Badalona, Spain
[4] Germans Trias & Pujol Hosp, Catalan Inst Oncol, Hematol Lab, Hematol,Mol Biol Unit, Badalona, Spain
[5] Germans & Trias Pujol Hlth Sci Res Inst IGTP, Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol ICO Badalona, Med Oncol, Badalona, Spain
[6] Germans & Trias Pujol Hlth Sci Res Inst, Lab Cellular & Mol Biol, Badalona, Spain
[7] Germans & Trias Pujol Hlth Sci Res Inst IGTP, Badalona Appl Res Grp Oncol B ARGO, St Pau & Santa Tecla Hosp, Med Oncol, Tarragona, Spain
[8] Catalan Inst Oncol ICO Badalona, Pharm, Badalona, Spain
[9] Germans Trias & Pujol Hosp, Otolaryngol, Badalona, Spain
[10] Autonomous Univ Barcelona UAB, Germans Trias & Pujol Hlth Sci Res Inst IGTP, Med Oncol, Badalona, Spain
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
965P
引用
收藏
页码：S681 / S681
页数：1
相关论文
共 17 条
  • [1] Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Cirauqui, Beatriz Cirauqui
    Peguera, Adria Bernat
    Pi-Sunyer, Ariadna Quer
    Ferrando-Diez, Angelica
    Serrano, Jose Luis Ramirez
    Vinolas, Marta Domenech
    Garcia, Iris Teruel
    Garcia, Vanesa Quiroga
    Oukadour, Imane Chaib
    Valencia, Andrea Gonzalez
    Vergara, Pilar Hernandez
    Egana, Itziar de Aguirre
    Herrero, Cristina Queralt
    Carbonell, Oscar Mesia
    Paradis, Assumpcio Lopez
    Esteve, Anna
    Vila, Mireia Margeli
    Rosell, Rafael
    Martinez-Cardus, Anna
    Mesia, Ricard
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025, 47 (01): : 57 - 67
  • [2] 5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3)
    Su, Yu-Chieh
    Wang, Chih-Chun
    Weng, Jui-Hsi
    Yeh, Shyh-An
    Chen, Po-Jen
    Hwang, Tzer-Zen
    Chen, Huang-Chi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
    Carinato, H.
    Burgy, M.
    Fischbach, C.
    Kalish-Weindling, M.
    Pabst, L.
    Frasie, V.
    Thiery, A.
    Coliat, P.
    Demarchi, M. F.
    Petit, T.
    Borel, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S668 - S668
  • [4] Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status.
    Gillison, M. L.
    Glisson, B. S.
    O'Leary, E.
    Murphy, B. A.
    Levine, M. A.
    Kies, M. S.
    Chan, D.
    Forastiere, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 282S - 282S
  • [5] Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.
    Carulla, Yannick
    Neidhardt, Eve-Marie
    Karabajakian, Andy
    Gauduchon, Thibault
    Guevara, Hemerson
    Roux, Pierre Eric
    Zrounba, Philippe
    Podeur, Fabien
    Poupart, Marc
    Excoffier, Aude
    Fayette, Jerome
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Intercellular contact augments epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3)-activation which increases podoplanin-expression in order to promote squamous cell carcinoma motility
    Fujii, Mizue
    Honma, Masaru
    Takahashi, Hidetoshi
    Ishida-Yamamoto, Akemi
    Iizuka, Hajime
    CELLULAR SIGNALLING, 2013, 25 (04) : 760 - 765
  • [8] Response to salvage chemotherapy with paclitaxel plus /cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
    Gomez, R. G. Herrera
    Saleh, K.
    Auclin, E.
    Vinches, M.
    Gervais, C.
    Espeli, V. G.
    Rothschild, S. I.
    Even, C.
    Cristina, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [9] FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E734 - E734
  • [10] FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab plus cetuximab in pts w/recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
    Bauman, J.
    Allman, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E36 - E36
12